Despite lower revenue, Zumiez's P/S ratio aligns with the industry, hinting at overlooked limited growth expectations. The weaker revenue outlook could lead to a share price and P/S ratio drop. A positive shift is needed to justify the current P/S ratio.
The company's CEO, Rick Brooks, stated that they are reviewing cost-saving strategies which could include closing underperforming stores and reducing labor costs. Despite the downbeat outlook, the company expects to open 10 new stores.
The three-year loss experienced by shareholders may indicate unresolved business challenges. This long-term share price weakness is generally considered a bad sign. However, some contrarian investors might research the stock in hope of a turnaround.
Ark Invest buys more Coinbase shares amid SEC crackdown Cathie Wood's Ark Invest boosted its holdings in$Coinbase (COIN.US)$amidst a crypto industry crackdown by the SEC, driving the stock to nearly five-month lows. Data from Cathie's Ark revealed that three of Wood's funds purchased over 400,000 Coinbase shares, with her main$ARK Innovation ETF (ARKK.US)$acquiring more than 300,000. This occurred as Coinbase's stock pri...
Gapping up $DocuSign (DOCU.US)$+16% (fiscal second-quarter earnings and revenue that topped Wall Street estimates and raised its forecast for fiscal-year billings.) $Zscaler (ZS.US)$+15% (the internet security platform issued a forecast better than Wall Street estimates.) $Tesla (TSLA.US)$+1.3% (The electric vehicle maker is considering building a lithium refinery for EV battery production in Texas this year, according to an applicati...
$Zumiez (ZUMZ.US)$Even after accounting for negative growth for the next 5 years, and lower margins, on my most conservative estimates this stock should be at least 2x in the coming years.
Gainers: •$Okta (OKTA.US)$+15.8% (In reaction to earnings) •$StoneCo (STNE.US)$+12.9% (In reaction to earnings) •$Turning Point Therapeutics (TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$Amylyx Pharmaceuticals (AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Zumiez Stock Forum
Zumiez Q3 Net Income USD 1.159 Million Vs. IBES Estimate USD 440 Thousand
Cathie Wood's Ark Invest boosted its holdings in $Coinbase (COIN.US)$ amidst a crypto industry crackdown by the SEC, driving the stock to nearly five-month lows. Data from Cathie's Ark revealed that three of Wood's funds purchased over 400,000 Coinbase shares, with her main $ARK Innovation ETF (ARKK.US)$ acquiring more than 300,000. This occurred as Coinbase's stock pri...
$DocuSign (DOCU.US)$ +16% (fiscal second-quarter earnings and revenue that topped Wall Street estimates and raised its forecast for fiscal-year billings.)
$Zscaler (ZS.US)$ +15% (the internet security platform issued a forecast better than Wall Street estimates.)
$Tesla (TSLA.US)$ +1.3% (The electric vehicle maker is considering building a lithium refinery for EV battery production in Texas this year, according to an applicati...
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
No comment yet